|
See Us At Our Booth - Number 2833
DAIC will be distributing recent product comparison charts and and offer copies of our most recent issue.
|
|
Current Issue:
September/October 2009
|
 |
| In this issue: |
• Outpatient cath labs
• Detecting Vulnerable Plaque
• Trends in ECG Monitoring
• Remote EP Monitoring Systems
• Stent Comparison Chart
• Prasugrel Enters the Anti-Platelet Market |
| |
| |
|
The Stent Tool Kit
Find out the latest development in the areas of bioabsorbable stent polymers, bioabsorbable stents, drug-eluting stents and bifurcation stents. Find out more>
|
|
|
|
Bioabsorbable Stents, Radial Access, Renals, Structural Heart Garner Interest at TCT Sessions
TCT has always been the event of the year to find out the latest information about stents, and for the first time in many years drug-eluting stents seem to be taking a back seat as cardiologists look forward to the next generations of bioabsorbable polymer coated DES and totally bioabsorbable stents. Some presenters at the DES Summit on Tuesday said there is not much new in DES technology except tweaks to current technology. Speakers advocated the next big leap forward is with bioabsorbable polymers, as with the Cordis NEVO, Boston Scientific JACTAX, and Abbott's totally bioabsorbable stent. Clinical trial data was also presented on the Genous, an endothelial cell progenerator stent, which does away with polymer and drugs in favor of promoting endothelial growth to help heal the vessel quickly. The summit was standing room only with hundreds of attendees.
A few other sessions have attracted larger than expected crowds and highlight growing trends in interventional cardiology. A session on renal interventions and another on transradial access spilled participants out into the hallways, where they stood to listen to the session audio piped into the hall by speakers.
Percutaneous structural heart interventions such as PFO occluders and especially transcatheter valves have made a strong showing. At an Edwards Lifesciences evening session Monday night concerning the SAPIEN Valve, Dr. Martin Leon said in opening remarks they only expected about 100 people, which caused a laugh among the hundreds of cardiologists who showed up unexpectedly. The evening symposium attendance at that session shows the growing interest in cath lab-based heart valve repair, which will likely become a reality in the U.S. in the next couple years. There are currently FDA trials for heart valves from Edwards, Evalve and Medtronic.
For more information about TCT, trial data and new products being highlighted at the show, visit out TCT FastPass Web site by clicking here: TCT FastPass Web site
Contact Dave Fornell at dfornell@sgcmail.com
|
|
:: Latest Technology
News & Updates
|
|
